Recombinant Mutant Human Tumor Necrosis Factor for Injection
[Dosage form] Freeze-dried powder for injection.
[Indication]
|
in the treatment of non-small cell lung cancer (NSCLC） |
Combined therapy with NP chemotherapy (NVB+DDP） |
|
Combined therapy with MVP chemotherapy vindesine+DDP+MMC） |
|
|
or in ineffective therapy for advanced or recurrent NSCLC patients with other methods |
|
|
in the treatment of non-Hodgkin's lymphoma（NHL） |
Combined therapy with BACOP chemotherapy |
|
(Cyclophosphamide +Vincristine +Doxorubicin ADM+Bleomycin +Prednisone ) |
|
|
or be used in trial by chemotherapy or other methods in the treatment of advanced NHL of invalid patients |
[Highlight]
•Promoting the concentration of chemotherapeutic drugs in tumor by 4 to 6 times
•Owning synergistic effect by combining various chemotherapeutics
•Promoting chemotherapeutic effect of advanced NSCLC and NHL significantly
•Effective rate is 87% in the treatment of Malignant pleural effusion applied as single drug
•Effective rate is 66.67% in the treatment of NHL applied as single drug
•The first recombinant mutant human tumor necrosis factor in the globe
2006-2025 上海博華國際展覽有限公司版權(quán)所有（保留一切權(quán)利）
滬ICP備05034851號(hào)-57
